Antibodies against TL1a and uses thereof

US10822422B2 · kind B2 · utility

Assignee

• TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · AU

Inventors

• Lynn Dorothy Poulton · Chatswood, AU
• Adam Clarke · Chatswood, AU
• Andrew James Pow · Burlingame, US
• Debra Tamvakis · Melbourne, AU
• George Kopsidas · Preston, AU
• Anthony G. Doyle · Chatswood, AU
• Philip Anthony Jennings · Chatswood, AU
• Matthew Pollard · Chatswood, AU

Key dates

• Filing date: Jul 11, 2016
• Grant date: Nov 3, 2020
• Expiry date: Aug 24, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.